296 related articles for article (PubMed ID: 31670006)
1. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Quiros-Roldan E; Castelli F; Bonito A; Vezzoli M; Calza S; Biasiotto G; Zanella I;
Cytokine; 2020 Feb; 126():154884. PubMed ID: 31670006
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
3. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
4. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
5. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Podany AT; Scarsi KK; Fletcher CV
Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
[TBL] [Abstract][Full Text] [Related]
6. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
10. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Yoshinaga T; Kobayashi M; Seki T; Miki S; Wakasa-Morimoto C; Suyama-Kagitani A; Kawauchi-Miki S; Taishi T; Kawasuji T; Johns BA; Underwood MR; Garvey EP; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2015 Jan; 59(1):397-406. PubMed ID: 25367908
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
13. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
14. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
[TBL] [Abstract][Full Text] [Related]
15. Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
Focà E; Calcagno A; Calza S; Renzetti S; Chiesa A; Siano M; De Socio G; Piconi S; Orofino G; Madeddu G; Cattelan AM; Nozza S; Ferrara M; Milic J; Celesia BM; Castelli F; Guaraldi G
PLoS One; 2021; 16(10):e0258533. PubMed ID: 34644336
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
17. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.
White KL; Raffi F; Miller MD
Viruses; 2014 Jul; 6(7):2858-79. PubMed ID: 25054884
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
19. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
20. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.
Giacomelli A; Ranzani A; Oreni L; Gervasi E; Lupo A; Ridolfo AL; Galli M; Rusconi S
Drug Des Devel Ther; 2019; 13():2271-2282. PubMed ID: 31371921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
